JP2018109017A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018109017A5 JP2018109017A5 JP2018021248A JP2018021248A JP2018109017A5 JP 2018109017 A5 JP2018109017 A5 JP 2018109017A5 JP 2018021248 A JP2018021248 A JP 2018021248A JP 2018021248 A JP2018021248 A JP 2018021248A JP 2018109017 A5 JP2018109017 A5 JP 2018109017A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cancer
- haloalkoxy
- haloalkylthio
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 25
- 125000006684 polyhaloalkyl group Polymers 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 21
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 20
- 201000011510 cancer Diseases 0.000 claims description 20
- 239000012453 solvate Substances 0.000 claims description 20
- 125000003545 alkoxy group Chemical group 0.000 claims description 19
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 18
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 18
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 18
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 18
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 17
- 150000001875 compounds Chemical class 0.000 claims description 17
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 17
- 125000004995 haloalkylthio group Chemical group 0.000 claims description 17
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 17
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 12
- 102000004495 STAT3 Transcription Factor Human genes 0.000 claims description 10
- 108010017324 STAT3 Transcription Factor Proteins 0.000 claims description 10
- 102000001712 STAT5 Transcription Factor Human genes 0.000 claims description 10
- 108010029477 STAT5 Transcription Factor Proteins 0.000 claims description 10
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 8
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 7
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 7
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 5
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 5
- 208000034578 Multiple myelomas Diseases 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 201000010881 cervical cancer Diseases 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 208000005017 glioblastoma Diseases 0.000 claims description 5
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 5
- 201000005787 hematologic cancer Diseases 0.000 claims description 5
- 201000007270 liver cancer Diseases 0.000 claims description 5
- 208000014018 liver neoplasm Diseases 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 201000000849 skin cancer Diseases 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000651 prodrug Substances 0.000 description 11
- 229940002612 prodrug Drugs 0.000 description 11
- 125000005843 halogen group Chemical group 0.000 description 10
- 125000004438 haloalkoxy group Chemical group 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 2
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- SXPRVMIZFRCAGC-UHFFFAOYSA-N 1,2,3,4,5-pentafluoro-6-methylbenzene Chemical compound CC1=C(F)C(F)=C(F)C(F)=C1F SXPRVMIZFRCAGC-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 241001553014 Myrsine salicina Species 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 125000004965 chloroalkyl group Chemical group 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 125000000262 haloalkenyl group Chemical group 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000000232 haloalkynyl group Chemical group 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261651757P | 2012-05-25 | 2012-05-25 | |
| US61/651,757 | 2012-05-25 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015514226A Division JP6290871B2 (ja) | 2012-05-25 | 2013-05-24 | 新しいサリチル酸誘導体、薬学上許容可能なその塩、その組成物及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018109017A JP2018109017A (ja) | 2018-07-12 |
| JP2018109017A5 true JP2018109017A5 (enExample) | 2018-08-23 |
| JP6543366B2 JP6543366B2 (ja) | 2019-07-10 |
Family
ID=49624538
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015514226A Expired - Fee Related JP6290871B2 (ja) | 2012-05-25 | 2013-05-24 | 新しいサリチル酸誘導体、薬学上許容可能なその塩、その組成物及びその使用方法 |
| JP2018021248A Expired - Fee Related JP6543366B2 (ja) | 2012-05-25 | 2018-02-08 | 新しいサリチル酸誘導体、薬学上許容可能なその塩、その組成物及びその使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015514226A Expired - Fee Related JP6290871B2 (ja) | 2012-05-25 | 2013-05-24 | 新しいサリチル酸誘導体、薬学上許容可能なその塩、その組成物及びその使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US9650399B2 (enExample) |
| EP (1) | EP2854819B1 (enExample) |
| JP (2) | JP6290871B2 (enExample) |
| CN (2) | CN105120854B (enExample) |
| BR (1) | BR112014029439A2 (enExample) |
| CA (1) | CA2874057A1 (enExample) |
| HK (1) | HK1218709A1 (enExample) |
| RU (1) | RU2641903C2 (enExample) |
| WO (1) | WO2013177534A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2975936A4 (en) * | 2013-03-22 | 2017-03-15 | University of Hawaii | Novel stat3 inhibitors |
| BR112016028022B1 (pt) * | 2014-05-30 | 2023-03-28 | The Governing Council Of The University Of Toronto | Compostos de sulfonamida inibidores de stat5 |
| US11299480B2 (en) | 2017-01-23 | 2022-04-12 | University Of Hawaii | 2-arylsulfonamido-N-arylacetamide derivatized STAT3 inhibitors |
| EP3898582A4 (en) * | 2018-12-21 | 2022-08-24 | The Governing Council of the University of Toronto | NEW SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY APPROVED SALT THEREOF, COMPOSITION THEREOF, AND METHODS OF USE THEREOF |
| US11485750B1 (en) | 2019-04-05 | 2022-11-01 | Kymera Therapeutics, Inc. | STAT degraders and uses thereof |
| JP2022549506A (ja) | 2019-09-27 | 2022-11-25 | ディスク・メディシン・インコーポレイテッド | 骨髄線維症および関連状態を処置するための方法 |
| EP4114371A4 (en) * | 2020-03-05 | 2024-04-17 | Centessa Pharmaceuticals (UK) Limited | ALPHA-SUBSTITUTED STAT INHIBITORS AND COMPOSITIONS THEREOF |
| CA3174623A1 (en) * | 2020-03-05 | 2021-09-10 | Janpix, Ltd. | Stat inhibitory compounds and compositions |
| KR20230012539A (ko) | 2020-05-13 | 2023-01-26 | 디스크 메디슨, 인크. | 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체 |
| CN112941036B (zh) * | 2021-02-08 | 2023-06-09 | 吉林惠康生物药业有限公司 | 一种提高狂犬病毒在人二倍体细胞中复制水平的方法 |
| CN114751927B (zh) * | 2022-03-08 | 2023-10-31 | 中山大学 | 一种硼酸化合物、制备方法及用途 |
| CN118994047B (zh) * | 2024-08-13 | 2026-02-10 | 中国药科大学 | 一种水杨醛衍生物及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1701941E (pt) * | 2003-12-11 | 2012-08-03 | Univ Texas | Compostos para o tratamento de doenças proliferativas celulares |
| PL2514742T3 (pl) * | 2006-03-31 | 2015-07-31 | Univ Texas | Leki przeciwnowotworowe będące pochodnymi kwasu kawowego dostępnymi biologicznie po podaniu doustnym |
| US7960434B2 (en) | 2006-05-19 | 2011-06-14 | University Of South Florida | Small molecule inhibitors of STAT3 with anti-tumor activity |
| UA95978C2 (ru) * | 2006-10-02 | 2011-09-26 | Оцука Фармас'Ютікел Ко., Лтд. | Ингибитор активации stat3/5 |
| US8466290B2 (en) * | 2008-07-10 | 2013-06-18 | Pharma Ip General Incorporated Association | STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient |
| CA2757912A1 (en) * | 2009-04-06 | 2010-10-14 | University Of Central Florida Research Foundation, Inc. | Compounds that suppress cancer cells and exhibit antitumor activity |
| KR20130121818A (ko) | 2010-08-02 | 2013-11-06 | 유니버시티 오브 센트럴 플로리다 리서치 파운데이션, 인코포레이티드 | Stat 단백질의 저해제로서의 치환된 2-히드록시-4-(2-(페닐설폰아미도)아세트아미도)벤조산 유사체 |
| EP2975936A4 (en) * | 2013-03-22 | 2017-03-15 | University of Hawaii | Novel stat3 inhibitors |
-
2013
- 2013-05-24 US US14/550,293 patent/US9650399B2/en not_active Expired - Fee Related
- 2013-05-24 RU RU2014152697A patent/RU2641903C2/ru not_active IP Right Cessation
- 2013-05-24 BR BR112014029439A patent/BR112014029439A2/pt not_active Application Discontinuation
- 2013-05-24 CN CN201380038486.1A patent/CN105120854B/zh not_active Expired - Fee Related
- 2013-05-24 JP JP2015514226A patent/JP6290871B2/ja not_active Expired - Fee Related
- 2013-05-24 CN CN201910222566.1A patent/CN110003104A/zh active Pending
- 2013-05-24 HK HK16106053.3A patent/HK1218709A1/zh unknown
- 2013-05-24 WO PCT/US2013/042689 patent/WO2013177534A2/en not_active Ceased
- 2013-05-24 CA CA2874057A patent/CA2874057A1/en not_active Abandoned
- 2013-05-24 EP EP13794722.2A patent/EP2854819B1/en active Active
-
2017
- 2017-03-30 US US15/475,108 patent/US10377780B2/en active Active
-
2018
- 2018-02-08 JP JP2018021248A patent/JP6543366B2/ja not_active Expired - Fee Related
-
2019
- 2019-06-25 US US16/451,883 patent/US20190382422A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015522551A5 (enExample) | ||
| RU2014152697A (ru) | Новые производные салициловой кислоты, их фармацевтически приемлемая соль, композиции и способ применения | |
| EP3630101B1 (en) | Tegavivint for use in the treatment of pulmonary fibrosis | |
| HUP0003644A2 (hu) | 2,3-Diaril-pirazolo[1,5-b]piridazin-származékok, ezeket tartalmazó gyógyászati készítmények ciklooxigenáz 2(COX-2) gátlására, valamint eljárás a vegyületek előállítására | |
| RU2015107803A (ru) | Производные дигидроксипиримидинкарбоновой кислоты и их применение в лечении, облегчении или предотвращении вирусного заболевания | |
| JP2008520719A5 (enExample) | ||
| JP2013532652A5 (enExample) | ||
| CN101711156A (zh) | 作为血管新生抑制剂的伊曲康唑的手性纯的异构物及羊毛甾醇14a-去甲基酶的抑制剂 | |
| JP2024509981A5 (enExample) | ||
| US20090075945A1 (en) | Phosphate-bearing prodrugs of sulfonyl hydrazines as hypoxia-selective antineoplastic agents | |
| EA200701780A1 (ru) | Противоопухолевое средство | |
| US20040254103A1 (en) | Water-soluble shps as novel alkylating agents | |
| JP2012509313A5 (enExample) | ||
| KR20190114955A (ko) | Mtor-deptor 상호작용의 저해제 및 이의 사용 방법 | |
| NL8100808A (nl) | 2-amino-3-hydroxy(fenyl)methylfenylazijnzuren, hun esters en amiden. | |
| RU2002102495A (ru) | Новые производные ксантона, их получение и применение в качестве лекарственного средства | |
| JP6790256B2 (ja) | フェノチアジン誘導体及びその使用方法 | |
| JP2008545803A5 (enExample) | ||
| RU2003105689A (ru) | Ингибиторы фосфатаз cdc25 | |
| US4510338A (en) | Resorcin derivatives, process for their preparation and pharmaceutical compositions containing them | |
| JP2003512424A (ja) | ６−メトキシ−２−ナフチル酢酸プロドラッグ | |
| EP1720849B1 (fr) | Derives de pyranone utiles pour le traitement du cancer | |
| RU2007141564A (ru) | Аминоалкиламидометилзамещенные производные 2-(4-сульфониламино)-3-гидрокси-2н-хроман-6-ила и лекарственные средства, содержащие эти соединения | |
| CA2888379A1 (fr) | Composes 3,4-bis(catechol)pyrrole-n-substitues, leur preparation et utilisation dans le traitement du cancer | |
| US12570685B2 (en) | 2-methoxyestradiol derivatives and medical uses thereof |